IGF2BP1 enhances an aggressive tumor cell phenotype by impairing miRNA-directed downregulation of oncogenic factors-Reference-Cited by-同舟云学术

IGF2BP1 enhances an aggressive tumor cell phenotype by impairing miRNA-directed downregulation of oncogenic factors

Published:2018-04-12 Issue:12 Volume:46 Page:6285-6303
ISSN:0305-1048
Container-title:Nucleic Acids Research
language:en
Short-container-title:

Author:

Müller Simon¹,Bley Nadine¹,Glaß Markus¹,Busch Bianca¹,Rousseau Vanessa¹,Misiak Danny¹,Fuchs Tommy¹,Lederer Marcell¹,Hüttelmaier Stefan¹

Affiliation:

1. Institute of Molecular Medicine, Section for Molecular Cell Biology, Faculty of Medicine, Martin Luther University Halle-Wittenberg, Kurt-Mothes-Str. 3a, 06120 Halle, Germany

Funder

DFG

Publisher

Oxford University Press (OUP)

Subject

Genetics

Link

http://academic.oup.com/nar/article-pdf/46/12/6285/25844755/gky229.pdf

Reference62 articles.

1. The impact of microRNAs on protein output;Baek;Nature,2008

2. MicroRNA biogenesis pathways in cancer;Lin;Nat. Rev. Cancer,2015

3. MicroRNAs in cancer: biomarkers, functions and therapy;Hayes;Trends Mol. Med.,2014

4. let-7 regulates self renewal and tumorigenicity of breast cancer cells;Yu;Cell,2007

5. The tumor suppressor microRNA let-7 represses the HMGA2 oncogene;Lee;Genes Dev.,2007

Cited by 110 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. AVJ16 inhibits the RNA binding protein IGF2BP1 in lung adenocarcinomas and prevents tumor growth in mice;2024-08-17

2. The oncofetal protein IMP1 regulates the transcriptomic landscape to drive early events in pancreatic cancer progression and growth;2024-07-02

3. Recent advances in the reciprocal regulation of m6A modification with non-coding RNAs and its therapeutic application in acute myeloid leukemia;Pharmacology & Therapeutics;2024-07

4. IGF2BP2 inhibits invasion and migration of clear cell renal cell carcinoma via targeting Netrin‐4 in an m⁶A‐dependent manner;Molecular Carcinogenesis;2024-05-23

5. Synchronous profiling of mRNA N6-methyladenosine modifications and mRNA expression in high-grade serous ovarian cancer: a pilot study;Scientific Reports;2024-05-07